Update 62-2: Blinatumomab: CD19-/CD3-Bispecific T-cell Engaging (BiTE®) Antibody for B-Cell Leukemia Immunotherapy---A First-in-Class Agent That Directs T cells to Tumor Cell Targets (ABSTRACT)

+

Blinatumomab (Blincyto) received accelerated approval for treatment of Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) in December 2014. Blinatumomab is a first-in-class bispecific antibody with high affinity towards both CD19 (expressed primarily on the surface B cells) and CD3 (found on T-lymphocytes) receptors.  (CLICK FOR eUPDATE 62-2 IN eSECTION VIII IN TOC)